Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations

被引：107
作者：
Costa, Daniel B. [1 ]
Schumer, Susan T. [1 ]
Tenen, Daniel G. [1 ]
Kobayashi, Susumu [1 ]
机构：
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Hematol Oncol, Boston, MA 02215 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 07期
关键词：
D O I：
10.1200/JCO.2007.14.9039
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1182 / 1184
页数：4
相关论文
共 7 条
  • [1] Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
    Balak, Marissa N.
    Gong, Yixuan
    Riely, Gregory J.
    Somwar, Romel
    Li, Allan R.
    Zakowski, Maureen F.
    Chiang, Anne
    Yang, Guangli
    Ouerfelli, Ouathek
    Kris, Mark G.
    Ladanyi, Marc
    Miller, Vincent A.
    Pao, William
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (21) : 6494 - 6501
  • [2] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
    Baselga, J
    Rischin, D
    Ranson, M
    Calvert, H
    Raymond, E
    Kieback, DG
    Kaye, SB
    Gianni, L
    Harris, A
    Bjork, T
    Averbuch, SD
    Feyereislova, A
    Swaisland, H
    Rojo, F
    Albanell, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) : 4292 - 4302
  • [3] Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib
    Cho, Byoung Chul
    Im, Chong-Kun
    Park, Moo-Suk
    Kim, Se Kyu
    Chang, Joon
    Park, Jong Pil
    Choi, Hye Jin
    Kim, Yu Jin
    Shin, Sang-Joon
    Sohn, Joo Hyuk
    Kim, Hoguen
    Kim, Joo Hang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18) : 2528 - 2533
  • [4] BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations
    Costa, Daniel B.
    Halmos, Balazs
    Kumar, Amit
    Schumer, Susan T.
    Huberman, Mark S.
    Boggon, Titus J.
    Tenen, Daniel G.
    Kobayashi, Susumu
    [J]. PLOS MEDICINE, 2007, 4 (10): : 1669 - 1680
  • [5] MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
    Engelman, Jeffrey A.
    Zejnullahu, Kreshnik
    Mitsudomi, Tetsuya
    Song, Youngchul
    Hyland, Courtney
    Park, Joon Oh
    Lindeman, Neal
    Gale, Christopher-Michael
    Zhao, Xiaojun
    Christensen, James
    Kosaka, Takayuki
    Holmes, Alison J.
    Rogers, Andrew M.
    Cappuzzo, Federico
    Mok, Tony
    Lee, Charles
    Johnson, Bruce E.
    Cantley, Lewis C.
    Janne, Pasi A.
    [J]. SCIENCE, 2007, 316 (5827) : 1039 - 1043
  • [6] Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
    Hidalgo, M
    Siu, LL
    Nemunaitis, J
    Rizzo, J
    Hammond, LA
    Takimoto, C
    Eckhardt, SG
    Tolcher, A
    Britten, CD
    Denis, L
    Ferrante, K
    Von Hoff, DD
    Silberman, S
    Rowinsky, EK
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) : 3267 - 3279
  • [7] EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
    Kobayashi, S
    Boggon, TJ
    Dayaram, T
    Janne, PA
    Kocher, O
    Meyerson, M
    Johnson, BE
    Eck, MJ
    Tenen, DG
    Halmos, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) : 786 - 792
1